Content area
Full Text
Market withdrawal of pioglitazone in France does not have an adverse impact on hospitalisations or deaths in diabetic patients, despite significant changes in the use of some T2DM· drugs.
This was the finding of a study that evaluated noninsulinic antidiabetic drug reimbursement data for the French population (utilising a healthcare insurance system) for the January 2010-December 2014 period.
Pioglitazone was withdrawn from the French market in August 2011 following "demonstration of a significant, but moderate, increase in the risk of bladder cancer (1.2-fold increase)", noted...